Aardvark Therapeutics, Inc. rose 16.1% on Wednesday, November 11, 2026, on 387,500 shares. No headline about AARD came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Aardvark Therapeutics, Inc. (AARD:NASDAQ) closed at $1.33 on November 13, 2026, down 12.50% on the day. The stock trades 92.0% below its 52-week high of $16.60 and 43.0% above its 52-week low of $0.930. Over the past year, it lost 87.2%. Aardvark Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, AARD closed higher on 126 days (50%). Its best day was July 10, 2026 (+52.00%) and its worst was October 23, 2026 (-64.81%). The stock moved 10% or more in a single session 31 times. It opened at least 5% above the previous day's high 2 times.
Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We have focused our efforts on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Our wholly-owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which we have initiated a Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS). We also intend to evaluate ARD-101 in a Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation (HO).
Find more stocks like AARD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.